Back to Search Start Over

Sofosbuvirā€based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection

Authors :
Ding-Shinn Chen
Tung-Hung Su
Jia-Horng Kao
Chun-Ming Hong
Pei-Jer Chen
Hung-Chih Yang
Chun-Jen Liu
Chen-Hua Liu
Tai-Chung Tseng
Source :
Journal of Gastroenterology and Hepatology. 34:1620-1625
Publication Year :
2019
Publisher :
Wiley, 2019.

Abstract

BACKGROUND AND AIM Data regarding the comparative effectiveness and safety of sofosbuvir (SOF) in combination with ribavirin (RBV), daclatasvir (DCV), or ledipasvir (LDV) for hepatitis C virus genotype 2 (HCV-2) patients were limited. We aimed to evaluate the performance of these regimens in Taiwan. METHODS One hundred eighty-seven HCV-2 patients with compensated liver diseases receiving SOF in combination with RBV (n = 82), DCV (n = 66), or LDV (n = 39) for 12 weeks were retrospectively enrolled. The effectiveness was determined by sustained virologic response 12 weeks off therapy (SVR12 ). The patient characteristics potentially related to SVR12 were compared. The safety profiles and laboratory abnormalities were assessed. RESULTS The SVR12 rates were 93.9% (95% confidence interval [CI]: 86.5-97.4%), 98.5% (95% CI: 91.9-99.7%), and 100% (95% CI: 91.0-100%) in patients receiving SOF combined with RBV, DCV, and LDV, respectively. All patients tolerated treatment well. The stratified SVR12 rates were comparable regardless of baseline characteristics or week 4 viral decline among these regimens. Six (3.2%) patients had serious adverse events which were not related to treatment. The rates of fatigue, pruritus, and anemia tended to be higher in patients receiving RBV (22.0%, 19.5%, and 8.5%) combination than those receiving DCV (10.6%, 6.1%, and 1.5%) or LDV (10.3%, 5.1%, and 0%) combination. CONCLUSIONS Sofosbuvir in combination with RBV, DCV, or LDV for 12 weeks is effective and well-tolerated for HCV-2 patients. Compared with DCV or LDV combination, the risks of fatigue, pruritus, and anemia are higher in patients receiving RBV combination.

Details

ISSN :
14401746 and 08159319
Volume :
34
Database :
OpenAIRE
Journal :
Journal of Gastroenterology and Hepatology
Accession number :
edsair.doi.dedup.....12162a68dcabf0043dc0c703ccac064c
Full Text :
https://doi.org/10.1111/jgh.14615